5 completed. 5 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Pupil Disorders: new trials by email Literature Review of Pupil Disorders trials Research Report on Pupil Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution IMP 08P2002F0, Mydriasert® insert - Mydriasis | Phase 1 / Phase 2 | Completed | Unither Pharmaceuticals, France | 20 | 2025-11-01 | 2026-06-17 |
| Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age Remifentanil Hydrochloride, Pupillometry measurement - Opioid Toxicity, Pupillary Miosis | Phase 2 / Phase 3 | Completed | University of California, San Francisco | 10 | 2022-10-01 | 2025-05-02 |
| Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) - Mydriasis, Dilation | Phase 2 | Completed | Opus Genetics, Inc | 32 | 2019-08-13 | 2026-10-30 |
| Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil MDD-administered EYN-1601, Phenylephrine 2.5% Eyedrop, Phenylephrine 10% Eyedrop - Mydriasis | Phase 2 | Completed | Eyenovia Inc. | 12 | 2016-10-01 | 2022-07-27 |
| Topical 0.4% Ketorolac and Vitreoretinal Surgery Ketorolac - Surgery | Phase 2 / Phase 3 | Completed | Emory University | 76 | 2006-11-01 | 2014-05-14 |
Mydriasis (4) · Dilatation, Pathologic (1) · Miosis (1) · Respiratory Insufficiency (1)
Eye Diseases (5) · Pathological Conditions, Signs and Symptoms (2) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Pathological Conditions, Anatomical (1) · Respiration Disorders (1) · Respiratory Tract Diseases (1) · Signs and Symptoms (1)
Ketorolac (1) · Ophthalmic Solutions (1) · Phenylephrine (1) · Remifentanil (1)
Emory University (1) · Eyenovia Inc. (1) · Opus Genetics, Inc (1) · Unither Pharmaceuticals, France (1) · University of California, San Francisco (1)
United States (4) · Greece (1)
Rachel Eshima McKay, MD (1) · Stephen J Kim, MD (1)